Company Profile
Pharming Group Stock Price, News & Catalysts
- Ticker:
- PHAR
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- United States
Stock performance
11.79 USD (+0.60%)
Close
Last updated: August 17, 2026
—
Market cap
Why the stock is moving
As of Aug 17, 2026, PHAR closed up 0.60% at $11.79. No new same-company headline was identified in the current news window.
Company overview
Global Rare-Disease Company
Pharming Group is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule and biologic medicines for rare, debilitating, and life-threatening diseases. Headquartered in Leiden, the Netherlands, the company operates in the United States and Europe and markets two rare-disease products across multiple international markets.
RUCONEST for Hereditary Angioedema
RUCONEST is an intravenous on-demand treatment for acute attacks of hereditary angioedema. Pharming positions the product for patients with high disease burden, including those experiencing severe or frequent attacks or inadequate outcomes with other on-demand therapies. The franchise is now primarily focused on the US market.
Joenja for APDS
Joenja, or leniolisib, is a targeted treatment for activated PI3K delta syndrome, a rare primary immunodeficiency caused by dysregulated PI3K delta signaling. The product is approved in the United States and an expanding group of international markets, with eligible populations varying by jurisdiction. Pharming combines commercialization with genetic diagnosis and patient-identification programs intended to find previously unrecognized APDS patients.
Leniolisib Expansion Beyond APDS
Pharming is evaluating leniolisib in two Phase 2 studies involving broader primary immunodeficiencies with immune dysregulation. One study enrolls patients with genetically defined disorders linked to altered PI3K delta signaling, while the other focuses on common variable immunodeficiency. The company expects the two studies to inform a single registrational Phase 3 strategy in the broader CVID population.
Mitochondrial-Disease Pipeline
Napazimone, formerly KL1333, is Pharming's pivotal-stage candidate for primary mitochondrial diseases caused by mitochondrial DNA mutations. The FALCON study is evaluating the therapy in adults with symptoms such as fatigue and muscle weakness and represents the company's principal clinical program outside the leniolisib franchise.
Future catalysts
- FDA PDUFA decision on the Joenja sNDA for certain children aged 4 to 11 years with APDS on October 24, 2026.
- Topline Phase 2 data for leniolisib in genetically defined primary immunodeficiencies linked to altered PI3K delta signaling in the fourth quarter of 2026.
- Topline Phase 2 data for leniolisib in CVID with immune dysregulation in the fourth quarter of 2026.
- Completion of enrollment in the pivotal FALCON study of napazimone in mitochondrial DNA-driven primary mitochondrial diseases during 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Pharming Group (PHAR)?
Pharming Group (PHAR) most recently closed at 11.79 USD, a +0.60% move versus the previous session.
What does Pharming Group do?
Global Rare-Disease Company Pharming Group is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule and biologic medicines for rare, debilitating, and life-threatening diseases. Headquartered in Leiden, the Netherlands, the company operates in the United States and Europe and markets two rare-disease products across...
On which exchange is PHAR stock listed?
Pharming Group (PHAR) is associated with NASDAQ, United States, Biotechnology.
What is Global?
Global Rare-Disease Company Pharming Group is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule and biologic medicines for rare, debilitating, and life-threatening diseases.
Which conditions is Pharming Group targeting with Global?
Pharming Group is associated with genetic disease based on its company overview and current catalyst commentary.
How does Pharming Group describe recent progress with Global?
FDA PDUFA decision on the Joenja sNDA for certain children aged 4 to 11 years with APDS on October 24, 2026. Topline Phase 2 data for leniolisib in genetically defined primary immunodeficiencies linked to altered PI3K delta signaling in the fourth quarter of 2026. Topline Phase 2 data for leniolisib in CVID with immune dysregulation in the fourth quarter of...
What is Rare-Disease?
Global Rare-Disease Company Pharming Group is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule and biologic medicines for rare, debilitating, and life-threatening diseases.
What should investors watch for with Rare-Disease?
FDA PDUFA decision on the Joenja sNDA for certain children aged 4 to 11 years with APDS on October 24, 2026. Topline Phase 2 data for leniolisib in genetically defined primary immunodeficiencies linked to altered PI3K delta signaling in the fourth quarter of 2026. Topline Phase 2 data for leniolisib in CVID with...